Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine for Cognitive Functioning in Bipolar I Disorder
NCT04771299Phase 3Terminated
- Start
- Jul 2021
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder and cognitive impairment comparing Cariprazine Arm with Placebo Arm (2 arms). Primary endpoints: Improvement in cognitive performance at 6 weeks and Improvement in functioning at 6 weeks. Started Jul 2021; status: terminated.
02
Drugs
cariprazine
03
Conditions
bipolar I disordercognitive impairment
Beyond the preview
Go deeper on NCT04771299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771299.